Glycogen storage disease: new approaches to therapy
- PMID: 95940
- DOI: 10.1002/9780470720363.ch17
Glycogen storage disease: new approaches to therapy
Abstract
Detailed studies of the effect of 32 days of intravenous alimentation on the metabolic, hormonal and clinical status of a 4-year-old boy with Type I glycogenosis revealed that the biochemical abnormalities and growth failure in this disorder are a consequence of glucose lack after brief periods of fasting which results from the inborn enzyme deficiency. Long-term (1.5-5.7 years) observations of the therapeutic effects of portacaval shunt without and with continuous overnight intragastic glucose by gastrostomy in two brothers, and of continuous overnight intragastric glucose alone in five other patients with this disorder, on metabolic status and physical growth and development suggest that adequate glucose can be provided by the intragastric route without hepatic portal circulatory by-pass. The introduction of this therapy in the first year of life should prevent the serious risk to life and long-term failure in growth and development previously observed in patients with Types I and III glycogenosis.
Similar articles
-
Portacaval shunt for glycogen storage disease and hyperlipidaemia.Ciba Found Symp. 1977;(55):311-25. doi: 10.1002/9780470720363.ch16. Ciba Found Symp. 1977. PMID: 207496
-
Portacaval shunt in siblings for type I glycogenosis.J Pediatr Surg. 1976 Aug;11(4):557-61. doi: 10.1016/s0022-3468(76)80012-7. J Pediatr Surg. 1976. PMID: 823318
-
Comparison of dietary therapy and portacaval shunt in the management of a patient with type Ib glycogen storage disease.J Pediatr Gastroenterol Nutr. 1987 Jul-Aug;6(4):635-9. doi: 10.1097/00005176-198707000-00025. J Pediatr Gastroenterol Nutr. 1987. PMID: 3123638
-
Glucose-6-phosphate: a key compound in glycogenosis I and favism leading to hyper- or hypolipidaemia.Eur J Pediatr. 1993;152 Suppl 1:S77-84. doi: 10.1007/BF02072094. Eur J Pediatr. 1993. PMID: 8319730 Review.
-
Emerging therapies for glycogen storage disease type I.Trends Endocrinol Metab. 2009 Jul;20(5):252-8. doi: 10.1016/j.tem.2009.02.003. Epub 2009 Jun 21. Trends Endocrinol Metab. 2009. PMID: 19541498 Review.
Cited by
-
Understanding Glycogen Storage Disease Type IX: A Systematic Review with Clinical Focus-Why It Is Not Benign and Requires Vigilance.Genes (Basel). 2025 May 15;16(5):584. doi: 10.3390/genes16050584. Genes (Basel). 2025. PMID: 40428406 Free PMC article. Review.
-
Dietary Management of the Glycogen Storage Diseases: Evolution of Treatment and Ongoing Controversies.Adv Nutr. 2020 Mar 1;11(2):439-446. doi: 10.1093/advances/nmz092. Adv Nutr. 2020. PMID: 31665208 Free PMC article. Review.
-
Hyperuricemia in glycogen storage disease type I. Contributions by hypoglycemia and hyperglucagonemia to increased urate production.J Clin Invest. 1985 Jan;75(1):251-7. doi: 10.1172/JCI111681. J Clin Invest. 1985. PMID: 2856925 Free PMC article.
-
Biochemical evidence for the requirement of continuous glucose therapy in young adults with type 1 glycogen storage disease.J Inherit Metab Dis. 1994;17(2):234-41. doi: 10.1007/BF00711624. J Inherit Metab Dis. 1994. PMID: 7967479 Clinical Trial.
-
The Eck fistula in animals and humans.Curr Probl Surg. 1983 Nov;20(11):687-752. doi: 10.1016/s0011-3840(83)80010-0. Curr Probl Surg. 1983. PMID: 6357642 Free PMC article.